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Quantitative Systems Pharmacology (QSP) has emerged recently as an approach that integrates
knowledge coming from multiple disciplines including drug pharmacology, systems biology,
physiology, mathematics and biochemistry. QSP was formally defined as a discipline and endorsed
in the NIH White Paper (Sorger et al., 2011) in 2011. It has emerged at a time when the
pharmaceutical industry is facing growing challenges in efficiency and productivity in R&D. QSP
has the potential to help overcome some of these challenges. QSP models allow researchers to
evaluate multiple hypotheses in-silico that would otherwise need to be evaluated experimentally.
There is an expectation that the use of QSP will reduce the cost of R&D and the risks associated
with uncertainties and gaps in our knowledge while bringing new therapies to patients.
QSPmodels are typically perceived as a research tool for hypothesis generation in drug discovery
and exploratory clinical development; however, recently the US FDA used a QSP model to
evaluate a proposed drug regimen for a new biologic therapy (Peterson and Riggs, 2015). In their
communication with NPS Pharma, the FDA’s Clinical Pharmacology division used a published
QSP model of the calcium homeostasis system (Peterson and Riggs, 2010) to recommend an
alternate dosing regimen for NATPARA, an injectable parathyroid hormone replacement drug used
to control low blood calcium in patients with hypoparathyroidism. The use of a QSP model by the
FDA to recommend an alternate dosing regimen to a sponsor highlights one of the important future
applications of QSP models in regulatory interactions, and also represents an important milestone
for the field. It is the first public instance of a QSPmodel being used by a regulatory agency to make
a clinical recommendation to a sponsor. In the future, it is anticipated that it will be sponsors that
leverage the utility of QSP models to support their own clinical decision making with regulatory
agencies.
In the present research topic entitled, “The Emerging Discipline of Quantitative Systems
Pharmacology,” we provide an introduction to the developing field of QSP with a series of articles
that describe models in different disease areas; showing how these models can be used to evaluate
important research questions in pharmaceutical R&D. The research topic starts with a perspective
article by Leil and Bertz (2014) that describes the history of how modeling tools where used
in pharmacology and in drug development. The authors point out two major reasons for the
growing importance of the QSP approach, (i) difficulty in finding new targets for therapies, and
(ii) increasing cost and time required for developing a successful drug. Integrated into the drug
development process, QSP modeling could become an effective tool to facilitate R&D; for example
to translate knowledge between experimental systems (e.g., animal to human), and to predict
the effects of multiple therapeutic interventions in combination; a task that would be inefficient
using only clinical experimentation. The other articles in the research topic go on to demonstrate
applications of QSP models to influence decision making in biomedical research.
One of the important applications of QSP modeling in pharmaceutical R&D is optimization
of clinical dose and schedule. Oncology is one of the disease areas where the narrow therapeutic
window of most therapeutics demands fine tuning of dose and schedule. Utilization of high doses
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of anti-angiogenesis therapy can result in rapid suppression
of angiogenesis and hypoxia leading to tumor shrinkage.
Paradoxically, this can subsequently lead to reduced drug delivery
to the tumor and resumption in tumor angiogenesis, followed
by progression of tumor growth. The paper by Sharan and Woo
(2015) discusses how to delay or prevent this from happening
by optimizing the dose and regimen of the anti-angiogenesis
therapies with a QSP model of angiogenesis.
Another important application of QSP models is to provide
mechanistic explanations for clinical data that are often
counterintuitive to the perceived mechanism of action (MoA) of
a drug. Despite the fact that two SGLT2 inhibitors are already
approved for use in patients, questions remain regarding their
MoA and why efficacy is lower than expected based on their high
potency and selectivity for SGLT2. The papers by Demin et al.
(2014) and Lu et al. (2014) explored this issue using mechanistic
models of renal tubular filtration and transport, incorporating
the PK and MoA of SGLT2 inhibitors. Lu et al. (2014) proposed
two possible explanations for the lower than expected efficacy;
the residual activity of SGLT2 following inhibition in the renal
tubules, and the compensatory effect of SGLT1. Demin et al.
(2014) supported this hypothesis, but also offered an alternative
in which the sites of action of SGLT2 inhibitors are located
not in the lumen of the kidney’s proximal tubules where the
concentration of SGLT2 inhibitor is high, but perhaps in the
proximal tubule where the concentration of inhibitor is lower.
Complex dose-response dependencies are often encountered in
many disease areas, for instance, in treatments of schizophrenia
as investigated by Spiros et al (Spiros et al., 2014). With the
use of a sophisticated QSP model of cognitive impairment in
schizophrenia, the authors predicted an inverse U-shape dose-
response with glycine that is a consequence of the shifting balance
between excitation and inhibition in the cortical network.
The application of mechanistic models for prediction of
target dependent or independent toxicity in secondary tissues
has been the focus of QSP for many years, as this is the
most common reason for termination of the development of
otherwise efficacious therapies. In order to predict toxicity using
a mechanistic model, it is useful to incorporate a physiologically
based PK (PBPK) model to predict drug concentrations in the
target organ. Woodhead et al. (2014) described the use of a
PBPK/toxicity model of drug induced liver injury (DILI) to
evaluate the impact of bile salt export pump (BSEP) inhibition
on hepatotoxicity in rats and humans. The DILI model was
used to predict the responses to BSEP inhibitors with and
without clinical hepatotoxicity. In accordance with the observed
clinical data, the model predicted that bosentan, but not
telmisartan, will cause mild hepatocellular ATP decline and
serum ALT elevation. Similar to the research by Woodhead
et al. (2014), Chetty et al. also relied on PBPK to predict drug
concentrations in tissue, linking these concentrations to target-
mediated pharmacodynamic (PD) effects (Chetty et al., 2014).
They did so using the Simcyp PBPK simulator, a tool that has
a built-in PBPK model and allows users to input drug specific
parameters that have been measured in-vitro to predict in-vivo
plasma and tissue PK. Simcyp has become an important tool
for pharmaceutical R&D and for communicating with regulatory
agencies regarding the PK of investigational drugs and their
potential PK-related drug-interactions. Chetty et al. described
the use of Simcyp to predict the tissue concentrations of four
different drugs, metoprolol, nifedipine, triazolam, and zolpidem
(Chetty et al., 2014). They demonstrated how polymorphisms
in drug metabolizing enzymes would have an effect on the
concentration of drugs in the target tissue and the subsequent
impact on pharmacodynamics.
One of the technical issues that potentially limit more
widespread use of QSP in biomedical research is the lack
of an accepted standard modeling tool to facilitate sharing
of models between researchers. The tool should permit
evaluation of experimental scenarios of interest in a flexible
computational environment for conducting efficient high
throughput simulation. A potential solution was implemented
in the web-based virtual systems pharmacology (ViSP) platform
described in the article by Ermakov et al. (2014). The salient
feature of ViSP is the use of a model in the form of an executable
file. Matched with a full set of model parameters this executable
becomes independent of the model structure and the software
that were used to develop themodel while preserving flexibility in
the input parameters. These characteristics could be useful in the
future when the utilization and sharing of QSP models becomes
more widespread.
In conclusion, we would like to emphasize the emerging
potential that QSP holds for biomedical research and in particular
to improve decision making in pharmaceutical R&D. In order
for this to occur, QSP will need to present more examples of the
value that it can bring to the process of hypothesis generation and
testing; examples like those included in this research topic.
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